Cologuard Plus™ test

The Cologuard Plus™ test is approved for average-risk patients 45 and older¹ and is backed by pivotal data from the 20,000+-person BLUE-C study published in the New England Journal of Medicine. Built on the proven performance of the Cologuard^® test, the Cologuard Plus test detects 95% of colorectal cancer (CRC) at 94% specificity in the U.S. screening population.¹*  It also detects 74% of high-grade dysplasia, the type of pre-cancerous growths most likely to advance to cancer.^† With its enhanced specificity, the Cologuard Plus test is expected to reduce unnecessary follow-up colonoscopies by up to 40% compared to the original Cologuard test. This performance makes the Cologuard Plus test the most accurate noninvasive CRC test reported in studies to date.^†

Like the original Cologuard test, the Cologuard Plus test maintains the convenience of at-home collection with no prep, diet restrictions, or sedation. It is shipped directly to a patient’s home and integrates with Exact Sciences’ technology platform, ExactNexus™, which simplifies ordering, result delivery, and patient navigation.